Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bayer AGXSWX:BAYN 50 Days Sales Outstanding is 75.60 as of Mar. 2026, which is 13% below its 10-year median of 87.37. GuruFocus rates XSWX:BAYN with a GF Score™ of 50/100 and a GF Value™ of CHF24.68 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 949 Drug Manufacturers companies, Bayer AG ranks worse than 67.54% on this metric.
Bayer AG's average Accounts Receivable for the
three
months ended in Mar. 2026 was CHF10,109 Mil. Bayer AG's Revenue for the
three
months ended in Mar. 2026 was CHF12,201 Mil.
Hence, Bayer AG's Days Sales Outstanding for the
three
months ended in Mar. 2026 was 75.60.
The historical rank and industry rank for Bayer AG's Days Sales Outstanding or its related term are showing as below:
XSWX:BAYN'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 71.69 Med: 87.37 Max: 109.17
Current: 93.76
During the past 13 years, Bayer AG's highest Days Sales Outstanding was 109.17. The lowest was 71.69. And the median was 87.37.
XSWX:BAYN's Days Sales Outstanding is ranked worse than 67.54% of 949
companies
in the Drug Manufacturers industry
Industry Median: 72
vs XSWX:BAYN: 93.76
Bayer AG's Days Sales Outstanding
increased
from Mar. 2025 (73.14) to Mar. 2026 (75.60).
Bayer AG (XSWX:BAYN) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Bayer AG Days Sales Outstanding Related Terms
Bayer AG Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Bayer AG's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:BAYN vs LLY, JNJ, ABBV: Days Sales Outstanding Comparison
For the Drug Manufacturers - General subindustry, Bayer AG's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bayer AG Days Sales Outstanding vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bayer AG's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Bayer AG's Days Sales Outstanding falls into.
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bayer AG (XSWX:BAYN) has a Days Sales Outstanding of 75.60 as of Mar. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Bayer AG and its competitors. This is 13% below median its historical median of 87.37. Over the past decade, Bayer AG's Days Sales Outstanding has ranged from 71.69 to 109.17. According to the industry distribution chart, Bayer AG ranks #641 out of 949 companies in the Drug Manufacturers industry, placing it in the top 67.5%.
Is Bayer AG's Days Sales Outstanding too high?
Bayer AG's current Days Sales Outstanding of 75.60 is 13% below median its 10-year median of 87.37. Over the past 10 years, this metric has ranged from a low of 71.69 to a high of 109.17. The Drug Manufacturers industry median Days Sales Outstanding is 72.00. Bayer AG's value of 75.60 is 5% above this industry median. Based on the distribution chart, Bayer AG ranks #641 out of 949 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Bayer AG has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bayer AG's Days Sales Outstanding compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Bayer AG ranks #641 out of 949 companies for Days Sales Outstanding. This places Bayer AG in the lower half of its industry. The industry median Days Sales Outstanding is 72.00. Bayer AG's value of 75.60 is 5% above this benchmark. Historically, Bayer AG's own Days Sales Outstanding has ranged from 71.69 to 109.17 over the past decade. While the company's 10-year median is 87.37 vs. the industry median of 72.00, Bayer AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Drug Manufacturers company?
The median Days Sales Outstanding among Drug Manufacturers companies is 72.00, based on 949 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bayer AG's current Days Sales Outstanding of 75.60 is 5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Bayer AG and its competitors. For the Drug Manufacturers industry, the median Days Sales Outstanding is 72.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bayer AG's current Days Sales Outstanding is 75.60, which is 13% below median its own 10-year median of 87.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bayer AG stock overvalued right now?
Based on GuruFocus' analysis, Bayer AG (XSWX:BAYN) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF24.68, compared to a current price of CHF44.18 — trading 79% above its estimated fair value. The current Days Sales Outstanding is 75.60, which is 13% below median its 10-year median of 87.37 and 5% above the Drug Manufacturers industry median of 72.00. Bayer AG's overall GF Score™ is 50/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Bayer AG (XSWX:BAYN), the current Days Sales Outstanding is 75.60 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bayer AG (XSWX:BAYN) Overvalued in 2026?
Based on GuruFocus' analysis, Bayer AG stock appears to be overvalued.
The current stock price of CHF44.18 is trading 79% above its estimated GF Value™ of CHF24.68.
GuruFocus considers Bayer AG to be Significantly Overvalued.
Key valuation signals for XSWX:BAYN:
Days Sales Outstanding: 75.60 (13% below median its 10-year median of 87.37)
GF Value™: CHF24.68 vs. price of CHF44.18 (79% above fair value)
Industry Position: 5% above the Drug Manufacturers median (#641 of 949)
No single metric tells the full story. See the XSWX:BAYN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bayer is a German healthcare and agriculture conglomerate. Healthcare provides close to half of the company's sales and includes pharmaceutical drugs (about 38% of total sales in 2025) as well as vitamins and other consumer healthcare products (13% of total). The firm's crop science business (47% of total) sells seeds, pesticides, herbicides, and fungicides, which was expanded through its 2018 acquisition of Monsanto.
50GF Score
Get the complete analysis for XSWX:BAYN
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:BAYN has been successfully added to your 
